<SEC-DOCUMENT>0001615219-22-000052.txt : 20220426
<SEC-HEADER>0001615219-22-000052.hdr.sgml : 20220426
<ACCEPTANCE-DATETIME>20220425174015
ACCESSION NUMBER:		0001615219-22-000052
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20220426
DATE AS OF CHANGE:		20220425

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Salarius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001615219
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				465087339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-231010
		FILM NUMBER:		22850969

	BUSINESS ADDRESS:	
		STREET 1:		2450 HOLCOMBE BLVD
		STREET 2:		SUITE J-608
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77021
		BUSINESS PHONE:		346-772-0346

	MAIL ADDRESS:	
		STREET 1:		2450 HOLCOMBE BLVD
		STREET 2:		SUITE J-608
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Flex Pharma, Inc.
		DATE OF NAME CHANGE:	20140730
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>denversalarius-prospectuss.htm
<DESCRIPTION>424B5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i731487425af54b57bab8205021f9c376_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Filed Pursuant to Rule 424(b)(5)<br>Registration No. 333-231010</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">PROSPECTUS SUPPLEMENT<br>(To Prospectus dated May 17, 2019)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:161%">9,339,436 Shares</font></div><div style="text-align:center"><img alt="image_2a.jpg" src="image_2a.jpg" style="height:104px;margin-bottom:5pt;vertical-align:text-bottom;width:282px"></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:161%">Common Stock</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">_____________________</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We are offering 9,339,436 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus to certain institutional investors. Our common stock is traded on the Nasdaq Capital Market under the symbol &#8220;SLRX.&#8221; On April 21, 2022, the last reported sale price of our common stock was $0.34 per share. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">In a concurrent private placement, we are also selling, to the purchasers of shares of our common stock in this offering, warrants to purchase an aggregate of 7,004,578 shares of our common stock (the &#8220;Private Placement Warrants&#8221;). The Private Placement Warrants and the shares of our common stock issuable upon exercise of the Private Placement Warrants are not being registered under the Securities Act of 1933, as amended, or the Securities Act, and are not being offered pursuant to this prospectus supplement and the accompanying prospectus but are being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We have retained Ladenburg Thalmann &#38; Co. Inc., the Placement Agent, as our exclusive placement agent to use its reasonable best efforts to solicit offers to purchase our securities in this offering.</font></div><div style="padding-left:52.02pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.961%"><tr><td style="width:1.0%"></td><td style="width:34.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></div><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per&#160;Share</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></div><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:-1.3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Offering price</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:1.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:1.5pt;margin-top:1.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.25</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:1.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:1.5pt;margin-top:1.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,334,859</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Placement agent&#8217;s fee(2)</font></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.02</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$186,788.72</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds to us, before expenses</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.23</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,148,070.28</font></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Only includes proceeds from, and Placement Agent fees related to, the issuance and sale of the common stock registered under the Securities Act pursuant to the registration statement of which this prospectus supplement and the accompanying base prospectus form a part. Does not include proceeds or fees related to the concurrent private placement. See &#8220;Private Placement of Warrants.&#8221;</font></div><div style="height:118.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">    </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">   </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;We have agreed to pay the Placement Agent an aggregate cash placement fee equal to 8% of the gross proceeds. In addition, we have agreed to pay certain expenses of the Placement Agent in this offering, as discussed under &#8220;Plan of Distribution.&#8221;</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The Placement Agent is not purchasing any securities pursuant to this prospectus supplement or the accompanying base prospectus. We expect that delivery of the securities being offered pursuant to this prospectus supplement will be made to purchasers on or about April 26, 2022.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">As of the date of this prospectus supplement, the aggregate market value of our outstanding common stock held by non-affiliates, or public float, was $15.7 million based on 46,290,126 shares of outstanding common stock, at a price of $0.34 per share, which was the last reported sale price of our common stock on the Nasdaq Capital Market on April 21, 2022. During the 12 full calendar months preceding the date of this prospectus, we have not sold any securities pursuant to General Instruction I.B.6 of Form S-3.</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">_____________________</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Investing in our common stock involves a high degree of risk.  Before buying any of our securities, you should carefully read the discussion of materials risks +of investing in our securities in the section entitled &#8220;Risk Factors&#8221; beginning on page S-5 of this prospectus supplement and in the documents we incorporate by reference into this prospectus supplement and the accompanying prospectus.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement and the accompanying prospectus.  Any representation to the contrary is a criminal offense.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We anticipate that delivery of the shares of common stock will be made through the facilities of the Depository Trust Company on or about April 26, 2022.</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">_____________________</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:161%">Ladenburg Thalmann</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">The date of this prospectus supplement is April 22, 2022</font></div><div><font><br></font></div><div style="height:118.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:161%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">    </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">   </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><div id="i731487425af54b57bab8205021f9c376_4"></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:161%">TABLE OF CONTENTS</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.427%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prospectus Supplement</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABOUT THIS PROSPECTUS SUPPLEMENT</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%;text-decoration:underline">S-i</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PROSPECTUS SUPPLEMENT SUMMARY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">S-1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">THE OFFERING</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_170" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%;text-decoration:underline">S-4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RISK FACTORS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_176" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%;text-decoration:underline">S-6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FORWARD-LOOKING STATEMENTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_182" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%;text-decoration:underline">S-9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USE OF PROCEEDS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_188" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%;text-decoration:underline">S-11</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRIVATE PLACEMENT OF WARRANTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_194" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">S-12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VOTING AGREEMENT</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_209" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">S-14</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DESCRIPTION OF CAPITAL STOCK</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_215" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">S-15</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PLAN OF DISTRIBUTION</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_221" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">S-17</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LEGAL MATTERS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_227" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">S-19</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXPERTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_233" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">S-19</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHERE YOU CAN FIND MORE INFORMATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_239" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">S-19</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INCORPORATION BY REFERENCE</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_245" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">S-20</a></font></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prospectus</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABOUT THIS PROSPECTUS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_251" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">i</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PROSPECTUS SUMMARY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_257" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RISK FACTORS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_263" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_269" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">9</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USE OF PROCEEDS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_275" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">11</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DESCRIPTION OF CAPITAL STOCK</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_281" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DESCRIPTION OF DEBT SECURITIES</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_292" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">19</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DESCRIPTION OF WARRANTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_287" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">27</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LEGAL OWNERSHIP OF SECURITIES</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_299" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">31</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PLAN OF DISTRIBUTION</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_305" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">36</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LEGAL MATTERS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_311" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%;text-decoration:underline">39</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXPERTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_317" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%;text-decoration:underline">39</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHERE YOU CAN FIND MORE INFORMATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_323" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">39</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i731487425af54b57bab8205021f9c376_329" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">40</a></font></div></td></tr></table></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="height:118.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:161%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">    </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">   </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><div id="i731487425af54b57bab8205021f9c376_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">ABOUT THIS PROSPECTUS SUPPLEMENT</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">This prospectus supplement and the accompanying prospectus are part of a registration statement on Form S-3 (No. 333-231010) that we filed with the Securities and Exchange Commission, or SEC, using a &#8220;shelf&#8221; registration process under the Securities Act.  Under the shelf registration process, we may offer shares of our common stock having an aggregate offering price of up to $100,000,000 from time to time under this prospectus supplement at prices and on terms to be determined by market conditions at the time of the offering.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">This document contains two parts.  The first part is this prospectus supplement, which describes the specific terms of this offering and also supplements and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus.  The second part is the accompanying prospectus, which provides more general information, some of which may not apply to this offering.  If the information contained in this prospectus supplement differs or varies from the information contained in the accompanying prospectus, you should rely on the information set forth in this prospectus supplement.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">This prospectus supplement, the accompanying prospectus and the documents we incorporate by reference herein and therein include important information about us and our common stock and other information you should know before investing.  We have not, and Ladenburg has not, authorized anyone else to provide you with information that is in addition to or different from that contained or incorporated by reference in this prospectus supplement and the accompanying prospectus, along with the information contained in any permitted free writing prospectuses we have authorized for use in connection with this offering.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The information contained in this prospectus supplement and the accompanying prospectus is accurate only as of the date of this prospectus supplement or the date of the accompanying prospectus, and the information in the documents incorporated by reference in this prospectus supplement and the accompanying prospectus is accurate only as of the date of those respective documents, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or of any sale of our common stock.  Our business, financial condition, results of operations and prospects may have changed since those dates.  It is important for you to read and consider all information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus in making your investment decision.  You should read both this prospectus supplement and the accompanying prospectus, as well as the documents incorporated by reference into this prospectus supplement and the accompanying prospectus and the additional information described under &#8220;Where You Can Find More Information&#8221; in this prospectus supplement and in the accompanying prospectus, before investing in our common stock.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We are offering to sell, and seeking offers to buy, the securities offered by this prospectus supplement only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of the securities offered by this prospectus supplement in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this </font></div><div style="height:134.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-i</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:161%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">    </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">   </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the Common Stock and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">All references in this prospectus supplement to &#8220;Salarius,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Salarius Pharmaceuticals, Inc. and its consolidated subsidiaries, except where the context otherwise requires or as otherwise indicated.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8220;Salarius Pharmaceuticals,&#8221; &#8220;SLRX&#8221; and the Salarius logo are our trademarks.  This prospectus supplement and the documents incorporated by reference into this prospectus supplement may also contain trademarks and trade names that are the property of their respective owners.  We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply relationships with, or endorsements or sponsorship of us by, these other companies. </font></div><div><font><br></font></div><div style="height:134.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-ii</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:161%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">    </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">   </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><div id="i731487425af54b57bab8205021f9c376_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">PROSPECTUS SUPPLEMENT SUMMARY</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:161%">This summary highlights certain information about us, this offering and the information appearing elsewhere in, or incorporated by reference in, this prospectus supplement and in the accompanying prospectus.  Because it is a summary, it does not contain all of the information that you should consider before investing.  Before investing in our common stock, you should read this entire prospectus supplement and the accompanying prospectus carefully, including the &#8220;Risk Factors,&#8221; and the financial statements and accompanying notes and other information incorporated by reference in this prospectus supplement and the accompanying prospectus.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Company Overview</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We are a clinical-stage biotechnology company focused on developing effective epigenetic-based cancer treatments for indications with high unmet medical need. Our lead epigenetic enzyme technology is a small molecule that inhibits the epigenetic enzyme lysine specific demethylase 1 (&#8220;LSD1&#8221;). We also recent acquired DRX-164, subsequently named as SP-3164, which is a next-generation cereblon binding molecular glue that we hope to deploy in hematological cancer and solid tumors.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Seclidemstat</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Epigenetics refers to the system that regulates gene expression through conformational changes to the chromatin rather than changes to the DNA sequence itself. Our lead compound, seclidemstat (&#8220;SP-2577&#8221;), is a small molecule that inhibits the epigenetic enzyme lysine specific demethylase 1 (&#8220;LSD1&#8221;). LSD1 is an enzyme that removes mono- and di-methyl marks on histones (core protein of chromatin) to alter gene expression. LSD1&#8217;s enzymatic activity can cause genes to turn on or off and thereby affect the cell&#8217;s gene expression and overall activity. In addition, LSD1 can act via its scaffolding properties, independently of its enzymatic function, to alter gene expression and modulate cell fate. In healthy cells, LSD1 is necessary for stem cell maintenance and cell development processes. However, in several cancers LSD1 is highly expressed and acts aberrantly to incorrectly silence or activate genes leading to disease progression. High levels of LSD1 expression are often associated with aggressive cancer phenotypes and poor patient prognosis. Hence, development of targeted LSD1 inhibitors is of interest for the treatment of various cancers. SP-2577 uses a novel, reversible mechanism to effectively inhibit LSD1&#8217;s enzymatic and scaffolding properties and thereby treat and prevent cancer progression.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Our first indication of interest for SP-2577 is a devastating bone and soft-tissue cancer called Ewing sarcoma. Ewing sarcoma mostly afflicts adolescents and young adults, with the median age of diagnosis being 15. The most commonly expressed fusion oncoprotein in Ewing sarcoma is the EWS-FLI fusion protein, which is present in approximately 85% of Ewing sarcoma cases. The LSD1 enzyme associates with EWS-FLI (and other E26 Transformation-Specific (&#8220;ETS&#8221;) fusion proteins) and is thought to promote tumorigenesis. We believe the SP-2577 molecule helps inhibit EWS-FLI activity by disrupting EWS-FLI from associating with coregulators (including LSD1) that are necessary for its cancer promoting activity. Therefore, we believe that SP-2577 can potentially </font></div><div style="height:134.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">reverse the aberrant gene expression and thereby possibly prevent Ewing sarcoma cell proliferation and even promote cell death. Preclinical studies of SP-2577 in certain Ewing sarcoma animal models show a significant tumor reduction as well as a significant survival benefit compared to untreated animals. Our ongoing Phase 1&#47;2 clinical trial is designed as a single agent dose escalation followed by a dose expansion study. The trial can enroll up to 50 relapsed or refractory Ewing sarcoma patients. The primary objectives of the study are to assess the safety and tolerability of SP-2577. Secondary objectives include assessing preliminary efficacy of SP-2577.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">As LSD1 can associate with over 60 regulatory proteins other than EWS-FLI, we believe that LSD1 may also play a critical role in progression of various other cancer types. These include both solid tumors and hematologic malignancies. In the second quarter of 2019, we initiated a second company-sponsored Phase 1 trial to study SP-2577 in Advanced Solid Tumors. The Advanced Solid Tumor (&#8220;AST&#8221;) trial is a single agent dose escalation, dose expansion study enrolling patients with advanced malignancies, excluding Ewing sarcoma or central nervous system tumors.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">In addition, recent data from &#8220;LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade&#8221; by W. Sheng, et al. and &#8220;Inhibition of Histone Lysine-specific Demethylase 1 Elicits Breast Tumor Immunity and Enhances Antitumor Efficacy of Immune Checkpoint Blockade&#8221; by Y. Qin, et al. suggests that LSD1 plays a role in tumor immune activity and can sensitize tumors to checkpoint inhibitors. These recent works have sparked interest in combining LSD1 inhibitors with checkpoint inhibitors. We are conducting preclinical work with SP-2577 in this area.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">SP-3164</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Our plan is to develop SP-3164 in high unmet need hematological and solid tumor indications. SP-3164's development in hematological indications leverages the clinical safety and efficacy data demonstrated by avadomide in hematological malignancies (e.g., Diffuse Large B cell Lymphoma, Follicular Lymphoma) across several clinical trials. SP-3164 is the stabilized, active S-enantiomer of avadomide, which exists as a 1&#58;1 ratio of the S and R enantiomers. However, only the S-enantiomer is the active, anti-cancer species. Therefore, because SP-3164 is the stabilized S-enantiomer, it has the potential to show improved therapy and safety over avadomide. This was demonstrated in early preclinical mouse models of multiple myeloma. In addition to having a clear development path</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:161%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">in hematological cancers, we believe SP-3164 also has potential in solid tumors. We are conducting preclinical work to identify the most promising indications and combinations for SP-3164's development in solid tumors.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Corporate Information</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We were incorporated as Flex Pharma, Inc. (&#8220;Flex Pharma&#8221;) in Delaware in February 2014. In July 2019, we changed our name to Salarius Pharmaceuticals, LLC following our merger with Salarius Pharmaceuticals, LLC. Our principal executive offices are located at 2450 Holcombe Blvd., Suite X, Houston, TX 77021, and our telephone number is (832) 834-6992. Our website address is www.salariuspharma.com. We do not incorporate the information </font></div><div style="height:134.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">on, or accessible through, our website into this prospectus, and you should not consider any information on, or accessible through, our website as part of this prospectus.</font></div><div style="height:134.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><div id="i731487425af54b57bab8205021f9c376_170"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:151%">THE OFFERING</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.154%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.646%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock offered by us</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,339,436 shares of our Common Stock.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Offering Price</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.25 per share.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock to be outstanding immediately after this offering</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,036,630 shares.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Use of proceeds</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">We estimate that the net proceeds to us from this offering will be approximately $2.0 million after deducting placement agent fees and other estimated offering expenses payable by us. </font></div><div style="margin-bottom:12pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">We intend to use the net proceeds from this offering for general corporate purposes and working capital, including in advancing our preclinical and clinical pipeline. See &#8220;Use of Proceeds&#8221; on page S-11 of this prospectus supplement.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private Placement Transaction</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:2.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In a concurrent private placement transaction (the &#8220;Private Placement Transaction&#8221;), we intend to sell to the purchasers in this offering unregistered warrants to purchase 75% of the shares of common stock purchased in this offering (the &#8220;Private Placement Warrants&#8221;). </font></div><div style="margin-bottom:12pt;margin-top:2.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Private Placement Warrants will be exercisable six months after the date of issuance at an exercise price of $0.3399 per share and will expire 66 months from the date of issuance. </font></div><div style="margin-bottom:12pt;margin-top:2.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Private Placement Warrants and the shares issuable upon exercise of the Private Placement Warrants have not been registered under the Securities Act, are not being offered pursuant to this prospectus supplement and the accompanying prospectus and are being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and&#47;or Rule 506(b) promulgated thereunder. See &#8220;Private Placement Transaction.&#8221;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk factors</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">See &#8220;Risk Factors&#8221; beginning on page S-6 of this prospectus supplement, and under similar headings in other documents filed after the date hereof and incorporated by reference into this prospectus supplement and the accompanying prospectus, for a discussion of factors you should consider carefully before deciding to invest in our common stock.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Capital Market symbol</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;SLRX&#8221;</font></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Unless otherwise indicated, the number of shares of common stock to be outstanding immediately after this offering is based on 45,241,808  shares outstanding as of December 31, 2021  and excludes as of such date&#58; NTD&#58; this is different number than highlighted above. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt"> 2,845,722 shares of common stock issuable upon the exercise of outstanding stock options as of January 20, 2022, with a weighted average exercise price of $1.75 per share&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">455,386 common stock issued on March 3, 2022 under the 2015 Equity Incentive Plan as part of the bonus payment for the year ended December 31, 2021&#59;</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">1,026,690 shares of common stock reserved for future issuance under our 2015 Equity Incentive Plan (the &#8220;2015 Plan&#8221;)&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">142,926 shares of common stock reserved for future issuance under our 2015 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) (as well as any future increases in the number of shares of common stock reserved for future issuance pursuant to the evergreen provision of the ESPP)&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">42,928 shares of common stock issuable upon exercise of a warrant issued to Wedbush Securities Inc. (&#8220;Wedbrush&#8221;), with an exercise price of $18.90 per share&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">3,783,522 shares of common stock issuable upon the exercise of warrants issued in connection with our public offering completed on February 11, 2020 (the &#8220;February Offering&#8221;), with an exercise price of $1.15 per share&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">3,964,065 shares of common stock issuable upon the exercise of warrants issued in a private placement completed on December 11, 2020 (the &#8220;Inducement Warrants&#8221;), with an exercise price of $1.182 per share&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">142,711 shares of common stock issuable upon the exercise of warrants that were distributed to holders of rights that were granted under that certain merger agreement that we entered into with Salarius Pharmaceuticals, LLC on January 3, 2019 (the &#8220;Flex Warrants&#8221;), with an exercise price of $15.17 per share&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">7,004,578 shares of common stock issuable upon exercise of the Private Placement Warrants. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Unless otherwise indicated, all information contained in this prospectus supplement assumes no exercise of the outstanding options and Private Placement Warrants described above.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div id="i731487425af54b57bab8205021f9c376_176"></div><div style="text-align:center;text-indent:18pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RISK FACTORS</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:161%">Investing in our common stock involves a high degree of risk.  Before making an investment decision, you should carefully consider the risks described below and in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K, as well as any amendments thereto reflected in subsequent filings, each of which are incorporated by reference in this prospectus supplement and the accompanying prospectus, and all of the other information in this prospectus supplement and the accompanying prospectus, including our financial statements and related notes incorporated by reference in this prospectus supplement and the accompanying prospectus.  If any of these risks is realized, our business, financial condition, results of operations and prospects could be materially and adversely affected.  In that event, the trading price of our common stock could decline and you could lose part or all of your investment.  Additional risks and uncertainties that are not yet identified or that we think are immaterial may also materially harm our business, operating results, and financial condition and could result in a complete loss of your investment.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Risks Related to This Offering</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Management will have broad discretion as to the use of the proceeds from this offering and may not use the proceeds effectively.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that may not improve our results of operation or enhance the value of our common stock. Our failure to apply these funds effectively could have a material adverse effect on our business and cause the price of our common stock to decline. See &#8220;Use of Proceeds&#8221; for a further description of how management intends to apply the proceeds from this offering.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Future sales of a significant number of our shares of common stock in the public markets, or the perception that such sales could occur, could depress the market price of our shares of our common stock or cause our stock price to decline.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Sales of a substantial number of our shares of common stock in the public markets (including sales of common stock issuable pursuant to the exercise of warrants or stock options), or the perception that such sales could occur, could cause the market price of our shares of common stock to decline and impair our ability to raise capital through the sale of additional equity securities.  A substantial number of shares of common stock are being offered by this prospectus.  We cannot predict the number of these shares that might be sold or resold, nor the effect that future sales of our shares of common stock, including the resale of shares issued in this offering, would have on the market price of our shares of common stock.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">We do not currently intend to pay dividends on our common stock, and any return to investors is expected to come, if at all, only from potential increases in the price of our common stock.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">At the present time, we intend to use available funds to finance our operations.  Accordingly, while payment of dividends rests within the discretion of the Board, we have no intention of paying any such dividends in the foreseeable future.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">If we fail to comply with the continued listing standards of Nasdaq, our common stock may be delisted from Nasdaq.  This in turn could result in significantly reduced trading liquidity, reduced trading volumes, and loss of research analyst coverage, among other consequences.  These in turn could result in a further decline in the market price of common stock and would have a material adverse effect on our company.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">On November 16, 2021, we were notified (the &#8220;Notice&#8221;) by Nasdaq that on November 15, 2021 the average closing price of the Company&#8217;s common stock (the &#8220;Common Stock&#8221;) over the prior 30 consecutive trading days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the &#8220;Minimum Bid Requirement&#8221;). To regain compliance, the closing bid price of the Company&#8217;s common stock must be at least $1.00 per share for a minimum of ten consecutive business days before May 16, 2022. On April 21, 2022, the closing price of our common stock was $0.34 per share. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">In the event that we do not regain compliance by May 16, 2022, we may be eligible for an additional 180 calendar day compliance period. To qualify, we would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market with the exception of the Minimum Bid Requirement and provide Nasdaq with written notice of our intention to cure the deficiency during the second compliance period. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We intend to actively monitor the closing bid price of our common stock and will evaluate available options to regain compliance with the Minimum Bid Requirement, such as implementing a reverse stock split. We currently plan to seek at our 2022 Annual Meeting of Stockholders the approval of our stockholders to implement a reverse stock split. There is no assurance that we will be able to obtain stockholder approval of the reverse stock split. In the event a reverse stock split is implemented, there is no assurance that the reverse stock split will not cause an actual decline in the value of our outstanding common stock. The liquidity of the shares of our common stock may be affected adversely by the reverse stock split given the reduced number of shares that will be outstanding following the reverse stock split, especially if the market price of our common stock does not increase as a result of the reverse stock split. In addition, the reverse stock split may increase the number of stockholders who own odd lots (less than 100 shares) of our common stock, creating the potential for such stockholders to experience an increase in the cost of selling their shares and greater difficulty effecting such sales. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">To the extent that we are unable to resolve any listing deficiency, including if our shareholders do not approve implementing a reverse stock split or it is unsuccessful in sufficiently raising the market price of our common stock, there is a risk that our common stock may be delisted from Nasdaq, which would adversely impact liquidity of our common stock and potentially result in even lower bid prices for our common stock and potentially result in even lower bid prices for our common stock.  If for any reasons, Nasdaq should delist our common stock, and if our common stock is not then eligible for quotation on another market or exchange, trading of shares of our common </font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">stock could be conducted in the over-the-counter markets.  In such event, a reduction in some or all of the following may occur, each of which could materially and adversely affect our stockholders&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">the liquidity of our common stock&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">the market price of our common stock&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">our ability to obtain financing for the continuation of our operations&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">the number of institutional and general investors that will consider investing in our common stock&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">the number of market makers in our common stock&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">the availability of information concerning the trading prices and volume of our common stock&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">the number of broker-dealers willing to execute trades in shares of our common stock.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The occurrence of any of these events could result in a further decline in the market price of common stock and could have a material adverse effect on us.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:center"><font><br></font></div><div id="i731487425af54b57bab8205021f9c376_182"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">FORWARD-LOOKING STATEMENTS</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">This prospectus supplement, the accompanying prospectus, and the documents we have filed with the SEC that are incorporated by reference in this prospectus supplement and the accompanying prospectus contain include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  These statements relate to future periods, future events, and our future operating or financial plans or performance.  All statements other than statements of fact, including statements identified by words such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;aim,&#8221; &#8220;target&#8221; and similar expressions are forward-looking statements, and include, but are not limited to, statements regarding the following&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">the Company's strategy and ongoing development programs&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">the Company's clinical trials, including status, costs and expectations related thereto&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">the Company's strategic collaborations and license agreements, intellectual property, FDA approval process and government regulation&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">the potential for seclidemstat to target the epigenetic dysregulation underlying Ewing sarcoma and advanced solid tumors including, but not limited to, prostate, breast, ovarian, melanoma, colorectal and other cancers&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">expected timing and results of clinical studies&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">the nature, strategy and focus of the company&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">the development and commercial potential of any product candidates&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">the Company's liquidity position and need for additional financing&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">the ability of the Company to access additional financing under the Grant Contract with Cancer Prevention and Research Institute of Texas&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">the Company's ability to continue as a going concern&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">future periods&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">competition in the markets in which we do business and our competitive advantages&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">our beliefs regarding our prospects for our business&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">the adequacy of our capital resources, our ability to raise additional financing, and the consequences if we fail to obtain adequate funding&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">our use of proceeds.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial requirements.  These statements are subject to known and unknown risks, uncertainties and assumptions that could cause actual results to differ materially from those projected or otherwise implied by the forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss in greater detail, and incorporate by reference into this prospectus supplement and the accompanying prospectus, many of these risks, uncertainties and assumptions under the heading &#8220;Risk Factors.&#8221;  Additional cautionary statements or discussions of risks, uncertainties, and assumptions that could affect our results or the achievement of the expectations described in forward-looking statements are also contained in the documents we incorporate by reference into this prospectus supplement.  </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Any forward-looking statement made by us in this prospectus supplement, or any of the documents incorporated by reference in this prospectus supplement speaks only as of the date on which it was made.  We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions, or circumstances on which any such statement is based.  You should, however, review additional disclosures we make in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the SEC.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">You should read this prospectus supplement, the accompanying prospectus, and the documents that we incorporated by reference in this prospectus supplement completely and with the understanding that our actual future results, levels of activity, and performance as well as other events and circumstances may be materially different from what we expect.  We qualify all of our forward-looking statements by these cautionary statements.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div id="i731487425af54b57bab8205021f9c376_188"></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">USE OF PROCEEDS</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We estimate that the net proceeds from this offering and the concurrent Private Placement Transaction will be approximately $2.0 million, after deducting the placement agent fees and commissions and estimated offering expenses payable by us. We intend to use the net proceeds from this offering for general corporate purposes and working capital, including in advancing our preclinical and clinical pipeline.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">This expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions, and our management will retain broad discretion as to the ultimate allocation of the proceeds. We may temporarily invest funds that we do not immediately need for these purposes in investment securities or use them to make payments on our borrowings.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-11</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div id="i731487425af54b57bab8205021f9c376_194"></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PRIVATE PLACEMENT OF WARRANTS</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Concurrently with the closing of the sale of common stock in this offering, pursuant to the securities purchase agreement, we are issuing and selling to the investors warrants to purchase an aggregate of up to 7,004,578 of common stock at an initial exercise price equal to $$0.3399 per share (the &#8220;Private Placement Warrants&#8221;).</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The Private Placement Warrants and the common stock issuable upon the exercise of the Private Placement Warrants are not being registered under the&#160;Securities Act, are not being offered pursuant to this prospectus supplement and the accompanying prospectus and are being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. Accordingly, the purchaser may only sell common stock issued upon exercise of the Private Placement Warrants pursuant to an effective registration statement under the&#160;Securities Act&#160;covering the resale of those shares, an exemption under Rule&#160;144&#160;under the&#160;Securities Act&#160;or another applicable exemption under the&#160;Securities Act.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Exercisability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:161%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#160;The Private Placement Warrants will be exercisable six months following issuance and expire on October 26, 2027. The Private Placement Warrants are exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and, at any time a registration statement registering the issuance of the common stock underlying the Private Placement Warrants under the&#160;Securities Act&#160;is effective and available for the issuance of such shares, or an exemption from registration under the&#160;Securities Act&#160;is available for the issuance of such shares, by payment in full in immediately available funds for the number of common stock purchased upon such exercise. If at the time of exercise there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the common stock underlying the Private Placement Warrants, then the Private Placement Warrants may also be exercised, in whole or in part, at such time by means of a cashless exercise, in which case the holder would receive upon such exercise the net number of common shares determined according to the formula set forth in the Warrant.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Exercise Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:161%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#160;A holder will not have the right to exercise any portion of the Private Placement Warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% (or 9.99% upon the request of the holder) of the number of common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Private Placement Warrants. However, any holder may increase or decrease such percentage, provided that any increase will not be effective until the 61st day after such election.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:161%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#160;The Private Placement Warrants will have an exercise price of $0.3399 per share. The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common shares and also upon any distributions of assets, including cash, stock or other property to our shareholders.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-12</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">. Subject to applicable laws, the Private Placement Warrants may be offered for sale, sold, transferred or assigned without our consent.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Exchange Listing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">. There is no established public trading market for the Private Placement&#160;Warrants&#160;being issued in the&#160;concurrent&#160;private&#160;placement, and we do not expect a market to develop. We do not intend to apply for listing of the Private Placement Warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the Private Placement Warrants will be limited.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Fundamental Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">. In the event of any fundamental transaction, as described in the Private Placement Warrants and generally including any merger with or into another entity, sale of all or substantially all of our assets, tender offer or exchange offer, or reclassification of our common stock, then upon any subsequent exercise of a Private Placement Warrant, the holder will have the right to receive as alternative consideration, for each Common Share that would have been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction, the number of common stock of the successor or acquiring corporation or of our company, if it is the surviving corporation, and any additional consideration receivable upon or as a result of such transaction by a holder of the number of common stock for which the Private Placement Warrant is exercisable immediately prior to such event.&#160; Additionally, as more fully described in the Private Placement Warrants, in the event of certain fundamental transactions, the holders will be entitled to receive consideration in an amount equal to the Black-Scholes&#160;value of the Private Placement Warrants on the date of consummation of such transaction.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Rights as a Shareholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">. Except as otherwise provided in the Private Placement Warrants or by virtue of such holder&#8217;s ownership of our common shares, the holder of a Private Placement Warrant does not have the rights or privileges of a holder of our common shares, including any voting rights, until the holder exercises the Private Placement Warrant.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Registration Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:161%">.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We have agreed to file a registration statement covering of the resale of the Private Placement Warrant Shares within 60 days of the date of the securities purchase agreement entered into between the purchasers and us. We must use commercially reasonable efforts to cause such registration statement to become effective as soon as practicable following the filing and to keep such registration statement effective at all times until the Purchaser no longer owns any Private Placement Warrants or Private Placement Warrant Shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-13</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div id="i731487425af54b57bab8205021f9c376_209"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">VOTING AGREEMENT</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The investors in this offering will be entering into voting agreements with the Company whereby each such investor will agree to vote all shares of common stock they beneficially own on the record date for our next stockholder meeting (which we anticipate will be on or about the date of the closing of this offering), including the shares purchased in the offering, with respect to any proposals presented to our stockholders at our next stockholders&#8217; meeting. Such investors&#8217; agreements to vote their shares of common stock in accordance with the immediately preceding sentence does not require the holder to vote its shares for or against any particular proposal or proposals.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-14</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div id="i731487425af54b57bab8205021f9c376_215"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">DESCRIPTION OF CAPITAL STOCK</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">This section describes the general terms and provisions of the shares of our common stock, par value $0.0001 per share.  This description is only a summary.  Our amended and restated certificate of incorporation, as amended and our amended and restated bylaws have been filed as exhibits to our periodic reports filed with the SEC, which are incorporated by reference in this prospectus.  You should read our amended and restated certificate of incorporation and our amended and restated bylaws for additional information before you buy any of our common stock, preferred stock or other securities.  See &#8220;Where You Can Find More Information.&#8221;</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Authorized Capital Stock</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Our authorized capital stock consists of 100,000,000 shares of common stock, $0.0001 par value per share, and 10,000,000 shares of preferred stock, $0.0001 par value per share.  As of December 31, 2021, Salarius had 45,241,808&#160;shares of common stock outstanding and no shares of preferred stock outstanding.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Common Stock </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Voting Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders.  The affirmative vote of holders of at least 66 2&#47;3% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, will be required to amend certain provisions of our amended and restated bylaws and our amended and restated certificate of incorporation, including provisions relating to amending our amended and restated bylaws, the classified board, the size of our board, removal of directors, director liability, vacancies on our board, special meetings, stockholder notices, actions by written consent and exclusive jurisdiction.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">. Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Liquidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">. In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Rights and Preferences</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock.  The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the future.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders.  The holders of our common stock do not have any cumulative voting rights.  Holders of our </font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-15</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock.  Our common stock has no preemptive rights, conversion rights, or other subscription rights or redemption or sinking fund provisions.  In the event of a liquidation, dissolution, or winding up of Salarius, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Listing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">.  Our common stock is listed on The Nasdaq Capital Market under the symbol &#8220;SLRX.&#8221;</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Transfer Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">.  The transfer agent and registrar for our common stock is American Stock Transfer &#38; Trust Company, LLC.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-16</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div id="i731487425af54b57bab8205021f9c376_221"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">PLAN OF DISTRIBUTION</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Ladenburg Thalmann &#38; Co. Inc., (the &#8220;Placement Agent&#8221;), has agreed to act as our exclusive placement agent in connection with this offering subject to the terms and conditions of the Placement Agency Agreement dated April 22, 2022. The Placement Agent is not purchasing or selling any of the shares of our common stock offered by this prospectus supplement, nor are they required to arrange the purchase or sale of any specific number or dollar amount of shares of our common stock, but have agreed to use its reasonable best efforts to arrange for the sale of all of the shares of our common stock offered hereby. Therefore, we will enter into securities purchase agreements directly with investors in connection with this offering and we may not sell the entire amount of shares of our common stock offered pursuant to this prospectus supplement. We will make offers only to a limited number of qualified institutional buyers and accredited investors. The Placement Agent is also acting as placement agent for the concurrent Private Placement Transaction.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fees and Expenses</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We have agreed to pay the Placement Agent a placement agent fee equal to 8.0% of the aggregate purchase price of the securities sold in this offering. The following table shows the per share and total cash placement agent fee we will pay to the Placement Agent in connection with the sale of the shares of our common stock offered pursuant to this prospectus supplement and the accompanying prospectus, assuming the purchase of all of the shares offered hereby.</font></div><div style="padding-left:21.14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"><tr><td style="width:1.0%"></td><td style="width:39.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.464%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.929%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Per Share</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.9pt;padding-right:4.9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.55pt"><font style="background-color:#cceeff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Offering price</font></div></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.25</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,334,859</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.35pt;padding-right:2.55pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Placement agent&#8217;s fee</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.02</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$186,788.72</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.55pt"><font style="background-color:#cceeff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds to us, before expenses</font></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.23</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2,148,070.28</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:6pt;text-indent:20pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">In addition, we have agreed to reimburse the Placement Agent&#8217;s expenses up to $75,000, inclusive of pre-closing and closing expenses. We estimate that the total expenses of the offering payable by us, excluding the placement agent fees and expenses, will be approximately $100,000.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The Placement Agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by it and any profit realized on the resale of the shares sold by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. As an underwriter, the Placement Agent would be required to comply with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities Act and Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of shares by the Placement Agent acting as principal. Under these rules and regulations, the Placement Agent&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">may not engage in any stabilization activity in connection with our securities&#59; and</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-17</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:14.5pt">may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation in the distribution.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discretionary Accounts</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The Placement Agent does not intend to confirm sales of the securities offered hereby to any accounts over which it has discretionary authority.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Relationships</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Upon completion of this offering, we have granted the Placement Agent a right of first refusal to act as joint bookrunner and&#47;or co-exclusive placement agent in connection with any subsequent public or private offering of equity securities or other capital markets financing by us. This right of first refusal extends for eight months from the closing date of this offering. The terms of any such engagement will be determined by separate agreement.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Ladenburg Thalmann &#38; Co. Inc. has performed investment banking services for us in the past, for which it has received customary fees and expenses. The Placement Agent and its respective affiliates may, from time to time, engage in transactions with or perform services for us in the ordinary course of their business.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock Listing</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our common stock is currently listed on the Nasdaq Capital Market under the symbol &#8220;SLRX.&#8221;</font></div><div style="text-indent:18pt"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transfer Agent and Registrar</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The transfer agent and registrar for our common stock is American Stock Transfer &#38; Trust Company, LLC.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Electronic Offer, Sale and Distribution of Shares</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">This prospectus supplement and the accompanying base prospectus may be made available in electronic format on websites or through other online services maintained by the Placement Agent, or by its affiliates. Other than this prospectus supplement and the accompanying base prospectus in electronic format, the information on the Placement Agent website and any information contained in any other websites maintained by the Placement Agent is not part of this prospectus supplement or the accompanying base prospectus or the registration statement of which this prospectus supplement and the accompanying base prospectus forms a part, has not been approved and&#47;or endorsed by us or the Placement Agent, and should not be relied upon by investors.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indemnification</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We have agreed to indemnify the Placement Agent against certain liabilities, including liabilities under the Securities Act of 1933, or to contribute to payments the Placement Agent may be required to make with respect to any of these liabilities.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-18</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div id="i731487425af54b57bab8205021f9c376_227"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">LEGAL MATTERS</font></div><div style="margin-bottom:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The validity of the common stock offered by this prospectus supplement will be passed upon for us by Hogan Lovells US LLP, Houston, Texas.  Ladenburg Thalmann &#38; Co. Inc. is being represented by Ellenoff Grossman &#38; Schole LLP, New York, New York, in connection with this offering.</font></div><div id="i731487425af54b57bab8205021f9c376_233"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">EXPERTS</font></div><div style="margin-bottom:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Ernst &#38; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the years ended December 31, 2021 and 2020, as set forth in their report, which is incorporated by reference in this prospectus supplement and elsewhere in the registration statement.  Our consolidated financial statements are incorporated by reference in reliance on Ernst &#38; Young LLP&#8217;s report, given on their authority as experts in accounting and auditing.</font></div><div id="i731487425af54b57bab8205021f9c376_239"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">WHERE YOU CAN FIND MORE INFORMATION</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We have filed a registration statement on Form S-3 with the SEC under the Securities Act.  This prospectus supplement and the accompanying prospectus is part of the registration statement but the registration statement includes and incorporates by reference additional information and exhibits.  We file annual, quarterly and current reports, proxy statements and other information with the SEC.  The SEC maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC.  The address of that site on the worldwide web is http&#58;&#47;&#47;www.sec.gov.  The information on the SEC&#8217;s web site is not part of this prospectus, and any references to this web site or any other web site are inactive textual references only.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-19</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div id="i731487425af54b57bab8205021f9c376_245"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">INCORPORATION BY REFERENCE</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We file annual, quarterly, and current reports, proxy statements, and other information with the SEC. The SEC maintains a web site that contains reports, proxy, and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of that site on the world wide web is http&#58;&#47;&#47;www.sec.gov. The information on the SEC&#8217;s web site is not part of this prospectus, and any references to this web site or any other web site are inactive textual references only. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The SEC permits us to &#8220;incorporate by reference&#8221; the information contained in documents we file with the SEC, which means that we can disclose important information to you by referring you to those documents rather than by including them in this prospectus supplement and the accompanying prospectus. Information that is incorporated by reference is considered to be part of this prospectus supplement and the accompanying prospectus and you should read it with the same care that you read this prospectus. Later information that we file with the SEC will automatically update and supersede the information that is either contained, or incorporated by reference, in this prospectus supplement and the accompanying prospectus, and will be considered to be a part of this prospectus supplement and the accompanying prospectus from the date those documents are filed. We have filed with the SEC, and incorporate by reference in this prospectus supplement and the accompanying prospectus (excluding any portions thereof furnished by the Registrant, including but not limited to information furnished under Item 2.02 and Item 7.01 and any exhibits relating to Item 2.02 or Item 7.01 furnished under Item 9.01 of Form 8-K and any certification required by 18 U.S.C. &#167; 1350)&#58; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (filed on March 25, 2022)&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">our Current Reports on Form 8-K filed with the SEC on January 13, 2022, April 1, 2022 and April 22, 2022&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:13.8pt">the description of our common stock contained in our Registration Statement on Form 8-A filed  on January 23, 2015, including any amendment or report filed for the purpose of updating such description.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We also incorporate by reference all additional documents that we file with the SEC under the terms of Section 13(a), 13(c), 14 or 15(d) of the Exchange Act that are made after the initial filing date of the registration statement of which this prospectus is a part and the effectiveness of the registration statement, as well as between the date of this prospectus and the termination of any offering of securities offered by this prospectus (excluding any portions thereof furnished by the Registrant, including but not limited to information furnished under Item 2.02 and Item 7.01 and any exhibits relating to Item 2.02 or Item 7.01 furnished under Item 9.01 of Form 8-K and any certification required by 18 U.S.C. &#167; 1350).</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Any statement contained in this Registration Statement or in a document incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to </font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-20</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">the extent that a statement contained in this Registration Statement or in any subsequently filed document that is deemed to be incorporated by reference in this Registration Statement modifies or supersedes such statement.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">You may request a copy of any or all of the documents incorporated by reference but not delivered with this prospectus, at no cost, by writing or telephoning us at the following address and number&#58; 2450 Holcombe Blvd., Suite X, Houston, TX 77021, and our telephone number is (832) 834-6992. We will not, however, send exhibits to those documents, unless the exhibits are specifically incorporated by reference in those documents.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We make available free of charge on our website our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports, as soon as reasonably practicable after we electronically file or furnish such materials to the Securities and Exchange Commission, or SEC. You may obtain a free copy of these reports in the Investor Relations section of our website, www.salariuspharma.com.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">S-21</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><div id="i731487425af54b57bab8205021f9c376_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">PROSPECTUS</font></div><div style="margin-bottom:10pt;text-align:center"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:324px"></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">$100,000,000</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Common Stock<br>Preferred Stock<br>Debt Securities<br>Warrants</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">_____________________</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">From time to time, we may offer up to $100,000,000 of any combination of the securities described in this prospectus in one or more offerings.  We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any applicable antidilution provisions.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">This prospectus provides a general description of the securities we may offer.  Each time we offer securities, we will provide specific terms of the securities offered in a supplement to this prospectus.  We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings.  The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus.  You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before you invest in any of the securities being offered.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">This prospectus may not be used to consummate a sale of any securities unless accompanied by a prospectus supplement.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Our common stock is listed on The Nasdaq Capital Market, or Nasdaq, under the symbol &#8220;FLKS.&#8221;  On April 22, 2019, the last reported sale price of our common stock was $0.55 per share.  The applicable prospectus supplement will contain information, where applicable, as to any other listing on Nasdaq or any securities market or other exchange of the securities, if any, covered by the prospectus supplement.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We will sell these securities directly to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis.  For additional information on the methods of sale, you should refer to the section titled &#8220;Plan of Distribution&#8221; in this prospectus.  If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts or over-allotment options will be set forth in a </font></div><div style="height:118.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:161%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">    </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">   </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">prospectus supplement.  The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The aggregate market value of our outstanding common stock held by non-affiliates was approximately $11.3 million which was calculated based on 18,043,229 shares of outstanding common stock held by non-affiliates as of April 1, 2019, and a price per share of $0.624, the closing price of our common stock on April 15, 2019.  Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities pursuant to this registration statement with a value more than one-third of the aggregate market value of our common stock held by non-affiliates in any 12-month period, so long as the aggregate market value of our common stock held by non-affiliates is less than $75.0 million.  In the event that subsequent to the effective date of this registration statement, the aggregate market value of our outstanding common stock held by non-affiliates equals or exceeds $75.0 million, then the one-third limitation on sales shall not apply to additional sales made pursuant to this registration statement.  We have not sold any securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to, and including, the date of this registration statement.</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">_____________________</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Investing in our securities involves a high degree of risk.  You should review carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus as described on page 6 of this prospectus.</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">_____________________</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.  Any representation to the contrary is a criminal offense.</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">_____________________</font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">The date of this prospectus is May 17, 2019.</font></div><div style="height:118.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:161%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">    </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">   </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><div id="i731487425af54b57bab8205021f9c376_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.427%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prospectus</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABOUT THIS PROSPECTUS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">i</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PROSPECTUS SUMMARY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">1</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RISK FACTORS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">7</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USE OF PROCEEDS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DESCRIPTION OF CAPITAL STOCK</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DESCRIPTION OF DEBT SECURITIES</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">15</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DESCRIPTION OF WARRANTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">22</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LEGAL OWNERSHIP OF SECURITIES</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">24</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PLAN OF DISTRIBUTION</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">28</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LEGAL MATTERS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%;text-decoration:underline">30</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXPERTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:187%;text-decoration:underline">30</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHERE YOU CAN FIND MORE INFORMATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">30</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;text-decoration:underline">31</font></div></td></tr></table></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="height:118.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:161%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">    </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><div id="i731487425af54b57bab8205021f9c376_251"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">ABOUT THIS PROSPECTUS</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">This prospectus is a part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or SEC, utilizing a &#8220;shelf&#8221; registration process.  Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one or more offerings up to a total aggregate offering price of $100,000,000.  This prospectus provides you with a general description of the securities we may offer.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Each time we sell securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of that offering.  We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings.  The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus.  You should read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the heading &#8220;Incorporation of Certain Information by Reference,&#8221; before investing in any of the securities offered.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Neither we, nor any agent, underwriter or dealer has authorized any person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus prepared by or on behalf of us or to which we have referred you.  This prospectus, any applicable supplement to this prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, any applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">This prospectus and the information incorporated herein by reference contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information.  All of the summaries are qualified in their entirety by the actual documents.  Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#8220;Where You Can Find More Information.&#8221;</font></div><div><font><br></font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">           i</font></div></div></div><div id="i731487425af54b57bab8205021f9c376_257"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">PROSPECTUS SUMMARY</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The following summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you need to consider in making your investment decision.  You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus.  You should also carefully read the information incorporated by reference into this prospectus, including our consolidated financial statements, and the exhibits to the registration statement of which this prospectus is a part.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Unless the context indicates otherwise, references in this prospectus to &#8220;Flex,&#8221;, &#8220;Flex Pharma&#8221;, &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar references refer to Flex Pharma, Inc. and its wholly owned subsidiaries.</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Company Overview</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We are a biotechnology company that was previously focused on developing innovative and proprietary treatments for muscle cramps, spasms and spasticity associated with severe neurological conditions.  In June 2018, we announced that we were ending our ongoing Phase 2 clinical trials of our lead drug product candidate, FLX-787, in patients with motor neuron disease, or MND, primarily with amyotrophic lateral sclerosis, or ALS, and in patients with Charcot-Marie-Tooth disease, or CMT, due to oral tolerability concerns observed in both studies.  The wind-down of the activities associated with these studies was completed in the third quarter of 2018.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">In 2016, we launched our consumer product, HOTSHOT &#174; , to prevent and treat exercise-associated muscle cramps, or EAMCs.  We continue to market and sell HOTSHOT to endurance athletes who drink it before, during and after exercise to prevent and treat exercise associated muscle cramps, or EAMCs.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">In June 2018, we initiated a process to explore a range of strategic alternatives for enhancing stockholder value, including the potential sale or merger of the Company.  Wedbush PacGrow was engaged to act as our strategic financial advisor at that time.  We also announced the restructuring of the organization to reduce our cost structure.  In connection with the restructuring plan, we reduced our workforce by approximately 60%, with the reduction completed as of September 30, 2018.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Following an extensive process of evaluating strategic alternatives and identifying and reviewing potential candidates for a strategic acquisition or other transaction, on January 3, 2019, we entered into a merger agreement with Salarius Pharmaceuticals, LLC, or Salarius, under which the privately held Salarius will merge with a wholly owned subsidiary of Flex Pharma.  If the merger is completed, the business of Salarius will continue as the business of the combined organization.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We expect to devote significant time and resources to completion of this merger.  However, there can be no assurance that such activities will result in the completion of the merger.  Further, the completion of the merger may ultimately not deliver the anticipated benefits or enhance shareholder value.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">If the merger is not completed, we will reconsider our strategic alternatives.  In this case, we consider one of the following courses of action to be the most likely alternatives&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:161%;padding-left:32.5pt">Dissolve and liquidate our assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">.  If, for any reason, the merger does not close, our Board of Directors will most likely conclude that it is in the best interest of stockholders to dissolve the Company and liquidate its assets.  In that event, we would be required to pay all of our debts and contractual obligations, and to set aside certain reserves for potential future claims.  There would be no assurances as to the amount or timing of available cash remaining to distribute to stockholders after paying our obligations and setting aside funds for reserves.</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:161%;padding-left:32.5pt">Pursue another strategic transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">.  We may resume the process of evaluating a potential strategic transaction in order to attempt another strategic transaction like the merger.</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:161%;padding-left:32.5pt">Operate the consumer business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">.  Although less likely than the alternatives above, our Board of Directors may elect to continue to market and sell HOTSHOT and continue to operate our consumer business.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We cannot predict whether or to what extent we might resume previous level of research and development activities, including clinical trials, or what the related future cash needs would be for any such activities.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Historical Business and Programs</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We focused our historical efforts on developing innovative and proprietary treatments for muscle cramps, spasms and spasticity associated with severe neurological conditions and exercise-associated muscle cramps.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Muscle cramps and spasms are involuntary, often painful, contractions that can last several minutes and, in many instances, result in prolonged soreness.  Muscle cramps and spasms are thought to result from hyperexcitable alpha-motor neurons.  Spasticity is characterized by the combination of weakness and velocity-dependent resistance to stretch, in the same muscle.  This reflex hyperexcitability may be due to lost inhibition in spinal cord circuits.  FLX-787, HOTSHOT and our other drug product candidates are based on a mechanism of action we describe as chemical neurostimulation.  We believe chemical neurostimulation to be a process in which a molecule, such as FLX-787, acts topically on the surfaces of the mouth, throat, esophagus and stomach to produce a sensory signal by activating nerves in those tissues.  That signal is thought to ultimately result in a beneficial effect.  Specifically, our product candidates activate certain receptors known as transient receptor potential, or TRP, ion channels in primary sensory neurons producing a signal believed to inhibit neuronal circuits and thereby reduce hyperexcitability in the neurons that fire muscles.  Reduced alpha-motor neuron hyperexcitability in spinal cord circuits is thought to suppress repetitive firing of alpha-motor neurons, thereby preventing or reducing muscle cramps and spasms, and potentially reducing reflex hyperexcitability and therefore spasticity.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">At the time we decided to stop our two Phase 2 clinical trials in June 2018, we were developing FLX-787 for severe neurological conditions.  We had recently completed a Phase 2 exploratory clinical trial in patients with Multiple Sclerosis, or MS, and were executing two Phase 2 clinical trials, one in MND and one in CMT.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">One Phase 2 clinical trial in the United States, referred to as the COMMEND trial, was in patients with MND, primarily with ALS, who suffered from muscle cramps.  FLX-787 was being developed for ALS under fast track designation which was granted by the Food and Drug Administration, or FDA, in July 2017.  The other Phase 2 clinical trial in the United States, referred to as the COMMIT trial, was in patients with CMT who suffered from muscle cramps.  We stopped these studies due to oral tolerability concerns observed in both studies.  In the COMMEND study, 31% of patients randomized to receive the oral disintegrating tablet formulation at 30 mg, taken three times a day, discontinued before the end of the 4-week treatment period due to oral adverse events.  A similar proportion of subjects in the COMMIT study discontinued due to oral adverse events, after being randomized to the 30 mg dose.  No patients randomized to the 0.5 mg low-dose control discontinued due to oral adverse events in either study.  The wind-down of the activities associated with these studies was completed in the third quarter of 2018.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">In addition to developing FLX-787, we also developed and launched our HOTSHOT consumer beverage in 2016.  HOTSHOT is our consumer beverage containing a proprietary formulation of TRP activators.  The majority of HOTSHOT sales are generated through our branded website and third-party websites.  We also sell HOTSHOT to select specialty retailers in geographic areas with strong endurance sports markets and directly to athletic teams at the amateur and professional levels.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">In January 22, 2018, we disclosed that we engaged an investment banking firm to assist with the consideration of strategic alternatives for our consumer business segment.  In connection with the restructuring plan announced in June&#160;2018, we elected to reduce the expenses associated with our consumer business segment while we assessed strategic alternatives for the Company and this segment.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Company Information</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We were incorporated in Delaware on February 26, 2014.  Our principal executive offices are located at 31 St. James Avenue, 6th Floor, Boston, Massachusetts 02116 and our telephone number is (617) 874-1821.  Our corporate website address is www.flex-pharma.com.  The information contained on our website is not a part of this prospectus, and the inclusion of our website address in the prospectus is an inactive textual reference only.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act.  We will cease to be an emerging growth company on the date that is the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.0 billion or more&#59; (ii) December 31, 2020&#59; (iii) the date on which we have issued more than $1.0 billion in non-convertible debt during the previous three years&#59; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">The Securities We May Offer</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We may offer shares of our common stock and preferred stock, various series of debt securities and warrants to purchase any of such securities, up to a total aggregate offering price of $100,000,000 from time to time in one or more offerings under this prospectus, together with any applicable prospectus supplement and any related free writing prospectus, at prices and on terms to be determined by market conditions at the time of the relevant offering.  This prospectus provides you with a general description of the securities we may offer.  Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">designation or classification&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">aggregate principal amount or aggregate offering price&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">maturity&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">original issue discount&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">rates and times of payment of interest or dividends&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">redemption, conversion, exchange or sinking fund terms&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">ranking&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">restrictive covenants&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">voting or other rights&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">conversion or exchange prices or rates and any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">important U.S. federal income tax considerations.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in documents we have incorporated by reference.  However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We may sell the securities directly to investors or through underwriters, dealers or agents.  We, and our underwriters or agents, reserve the right to accept or reject all or part of any proposed purchase of securities.  If we do offer securities through underwriters or agents, we will include in the applicable prospectus supplement&#58;</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">&#183;&#160;&#160;&#160;&#160;the names of those underwriters or agents&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">&#183;&#160;&#160;&#160;&#160;applicable fees, discounts and commissions to be paid to them&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">&#183;&#160;&#160;&#160;&#160;details regarding over-allotment options, if any&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">&#183;&#160;&#160;&#160;&#160;the estimated net proceeds to us.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">.  We may issue shares of our common stock from time to time.  Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders and does not have cumulative voting rights.  Subject to preferences that may apply to any outstanding preferred stock, holders of our common stock are entitled to receive ratably any dividends that our board of directors may declare out of funds legally available for that purpose.  In the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preference of any outstanding preferred stock.  Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock.  The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the future.  In this prospectus, we have summarized certain general features of our common stock under the heading &#8220;Description of Capital Stock-Common Stock.&#8221;  We urge you, however, to read the applicable prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to any common stock being offered.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">.  We may issue shares of our preferred stock from time to time, in one or more series.  Under our certificate of incorporation, our board of directors has the authority, without further action by our stockholders (unless such stockholder action is required by applicable law or the rules of any stock exchange or market on which our securities are then traded), to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the number, rights, preferences, privileges and restrictions thereof.  These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences and sinking fund terms, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock.  Any convertible preferred stock we may issue will be convertible into our common stock or exchangeable for our other securities.  Conversion may be mandatory or at the holder&#8217;s option and would be at prescribed conversion rates.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">If we sell any series of preferred stock under this prospectus, we will fix the designations, voting powers, preferences and rights of such series of preferred stock, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series.  We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form </font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">of any certificate of designation that describes the terms of the series of preferred stock that we are offering before the issuance of the related series of preferred stock.  In this prospectus, we have summarized certain general features of the preferred stock under the heading &#8220;Description of Capital Stock-Preferred Stock.&#8221;  We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred stock.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Debt Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">.  From time to time, we may issue debt securities in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt.  The senior debt securities will rank equally with any other unsecured and unsubordinated debt.  The subordinated debt securities will be subordinate and junior in right of payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness.  Convertible debt securities will be convertible into or exchangeable for our common stock or other securities.  Conversion may be mandatory or at the holder&#8217;s option and would be at prescribed conversion rates.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Any debt securities issued under this prospectus will be issued under one or more documents called indentures, which are contracts between us and a national banking association or other eligible party, as trustee.  In this prospectus, we have summarized certain general features of the debt securities under the heading &#8220;Description of Debt Securities.&#8221;  We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of debt securities being offered, as well as the complete indenture(s) and any supplemental indentures that contain the terms of the debt securities.  We have filed a form of indenture as an exhibit to the registration statement of which this prospectus is a part.  We will file as exhibits to the registration statement of which this prospectus is a part, or will be incorporated by reference from reports that we file with the SEC, supplemental indentures and forms of debt securities containing the terms of the debt securities being offered.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">.  We may issue warrants for the purchase of common stock, preferred stock or debt securities, in one or more series, from time to time.  We may issue warrants independently or in combination with common stock, preferred stock or debt securities.  In this prospectus, we have summarized certain general features of the warrants under the heading &#8220;Description of Warrants.&#8221;  We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants.  We have filed forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants that we may offer as exhibits to the registration statement of which this prospectus is a part.  We will file as exhibits to the registration statement of which this prospectus is a part, or will be incorporated by reference from reports that we file with the SEC, the form of warrant or the warrant agreement and warrant certificate, as applicable, that contain the terms of the particular series of warrants we are offering, and any supplemental agreements, before the issuance of such warrants.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Any warrants issued under this prospectus may be evidenced by warrant certificates.  Warrants may be issued under a warrant agreement that we enter into with a warrant agent.  We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular series of warrants being offered.</font></div><div><font><br></font></div><div style="margin-bottom:0.1pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify;text-indent:18pt"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.1pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:10pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.1pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.1pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.1pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font><br></font></div><div style="margin-bottom:0.1pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font><br></font></div><div style="margin-bottom:10pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font><br></font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><div id="i731487425af54b57bab8205021f9c376_263"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">RISK FACTORS</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Investing in our securities involves a high degree of risk.  You should carefully review the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in our Annual Report on Form 10-K for the year ended December&#160;31,&#160;2018, as updated by our subsequent filings, which are incorporated by reference into this prospectus, before deciding whether to purchase any of the securities being registered pursuant to the registration statement of which this prospectus is a part.  Each of the risk factors could adversely affect our business, results of operations, financial condition and cash flows, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment.  Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><div id="i731487425af54b57bab8205021f9c376_269"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">This prospectus and the documents incorporated by reference contain forward-looking statements.  These are based on our management&#8217;s current beliefs, expectations and assumptions about future events, conditions and results and on information currently available to us.  Discussions containing these forward-looking statements may be found, among other places, in the sections titled &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; incorporated by reference from our most recent Annual Report on Form 10-K, as well as any amendments thereto, filed with the SEC.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Any statements in this prospectus, or incorporated herein, about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements.  Within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, these forward-looking statements include statements regarding&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the timing and anticipated completion of the merger with Salarius Pharmaceuticals, LLC&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the expected benefits and growth potential of HOTSHOT&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">our ability to obtain funding for our operations if the merger is not completed&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">our ability to expand the sales of our consumer product&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the size and growth potential of the markets for our consumer product and our drug product candidates, and our ability to serve those markets&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the rate and degree of market acceptance of our consumer product&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the performance of our third-party suppliers and manufacturers&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the success of competing therapies that are, or become, available&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">our plans to resume development of our drug product candidates&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the loss of key scientific or management personnel&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">our expectations regarding the period during which we qualify as an emerging growth company under the Jumpstart Our Business Startups Act&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">our expectations regarding our ability to obtain and adequately maintain sufficient intellectual property protection for our consumer product and drug product candidates.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">In some cases, you can identify forward-looking statements by terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expects,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative or plural of those terms, and similar expressions intended to identify statements about the future, although not all forward-looking statements contain these words.  These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">You should refer to the &#8220;Risk Factors&#8221; section contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus, for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements.  Given these risks, uncertainties and other factors, many of which are beyond our control, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate, and you should not place undue reliance on these forward-looking statements.  Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material.  In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to revise any forward-looking statements to reflect events or developments occurring after the date of this prospectus, even if new information becomes available in the future.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></div></div><div id="i731487425af54b57bab8205021f9c376_275"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">USE OF PROCEEDS</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby.  Except as described in any applicable prospectus supplement or in any free writing prospectuses that we may authorize to be provided to you in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered hereby, if any, for working capital and general corporate purposes.  We will set forth in the applicable prospectus supplement or free writing prospectus our intended use for the net proceeds received from the sale of any securities sold pursuant to the prospectus supplement or free writing prospectus.  Pending the use of net proceeds, we intend to invest the net proceeds in short-term, investment-grade, interest-bearing obligations, certificates of deposit or direct or guaranteed obligations of the United States.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></div></div><div id="i731487425af54b57bab8205021f9c376_281"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">DESCRIPTION OF CAPITAL STOCK</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:161%">The following description of our capital stock and provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries.  You should also refer to the amended and restated certificate of incorporation and the amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus is part.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">General</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Under our amended and restated certificate of incorporation we are authorized to issue up to 100,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock are undesignated.  Our board of directors may establish the rights and preferences of the preferred stock from time to time.  As of April 15, 2019, we had outstanding 18,069,476 shares of common stock.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Common Stock </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Voting Rights</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders.  The affirmative vote of holders of at least 66 2&#47;3% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, will be required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to amending our amended and restated bylaws, the classified board, the size of our board, removal of directors, director liability, vacancies on our board, special meetings, stockholder notices, actions by written consent and exclusive jurisdiction.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Dividends</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Liquidation</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Rights and Preferences</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock.  The rights, preferences and privileges of the </font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the future.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Preferred Stock</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Pursuant to our amended and restated certificate of incorporation, our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the number, rights, preferences, privileges and restrictions thereof.  These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences and sinking fund terms, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock.  The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation.  In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change of control or other corporate action, or make the removal of management more difficult.  Additionally, the issuance of preferred stock may have the effect of decreasing the market price of the common stock.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Our board of directors will fix the designations, voting powers, preferences and rights of each series, as well as the qualifications, limitations or restrictions thereof, of the preferred stock of each series that we offer under this prospectus and applicable prospectus supplements in the certificate of designation relating to that series.  We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of that series of preferred stock.  This description will include&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the title and stated value&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the number of shares we are offering&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the liquidation preference per share&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the purchase price per share&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the dividend rate per share, dividend period and payment dates and method of calculation for dividends&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">our right, if any, to defer payment of dividends and the maximum length of any such deferral period&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the procedures for any auction and remarketing, if any&#59;</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the provisions for a sinking fund, if any&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">any listing of the preferred stock on any securities exchange or market&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">whether the preferred stock will be convertible into our common stock or other securities of ours, including depositary shares and warrants, and, if applicable, the conversion period, the conversion price, or how it will be calculated, and under what circumstances it may be adjusted&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange period, the exchange price, or how it will be calculated, and under what circumstances it may be adjusted&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">voting rights, if any, of the preferred stock&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">preemption rights, if any&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">restrictions on transfer, sale or other assignment, if any&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">whether interests in the preferred stock will be represented by depositary shares&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">a discussion of any material or special U.S. federal income tax considerations applicable to the preferred stock&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs&#59; 11</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">any limitations on issuances of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock being issued as to dividend rights and rights if we liquidate, dissolve or wind up our affairs&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">any other specific terms, rights, preferences, privileges, qualifications or restrictions of the preferred stock.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The Delaware General Corporation Law, or DGCL, which is the law of the state of our incorporation, provides that the holders of preferred stock will have the right to vote separately as a class (or, in some cases, as a series) on an amendment to our certificate of incorporation if the amendment would change the par value, the powers, preferences or special rights of the class or series so as to adversely affect the class or series, as the case may be, or, unless the certificate of incorporation provided otherwise, the number of authorized shares of the class.  This right is in addition to any voting rights that may be provided for in the applicable certificate of designation.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Anti-Takeover Provisions</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Section 203 of the Delaware General Corporation Law</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We are subject to Section 203 of the DGCL, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2&#47;3% of the outstanding voting stock that is not owned by the interested stockholder.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">In general, Section 203 defines a &#8220;business combination&#8221; to include the following&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">any merger or consolidation involving the corporation and the interested stockholder&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder&#59; or</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">In general, Section 203 defines an &#8220;interested stockholder&#8221; as an entity or person who, together with the entity or person&#8217;s affiliates and associates, beneficially owns, or is an affiliate or associate of the corporation and within three </font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Among other things, our amended and restated certificate of incorporation and amended and restated bylaws will&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change in control&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">provide that the authorized number of directors may be changed only by resolution of our board of directors&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">provide that our board of directors will be classified into three classes of directors&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">provide that, subject to the rights of any series of preferred stock to elect directors, directors may only be removed for cause, which removal may be effected, subject to any limitation imposed by law, by the holders of at least a majority of the voting power of all of our then-outstanding shares of the capital stock entitled to vote generally at an election of directors&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent or electronic transmission&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#8217;s notice&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">provide that special meetings of our stockholders may be called only by the chairman of our board of directors, our chief executive officer or president or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">The amendment of any of these provisions would require approval by the holders of at least 66&#160;2&#47;3&#160;%&#160;of the voting power of all of our then-outstanding common stock entitled to vote generally in the election of directors, voting together as a single class.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The combination of these provisions will make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors.  Because our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management.  In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage coercive takeover practices and inadequate takeover bids.  These provisions are also designed to reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights.  However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control or management.  As a consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts.  We believe that the benefits of these provisions, including increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages of discouraging takeover proposals, because negotiation of takeover proposals could result in an improvement of their terms.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:161%">Choice of Forum</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Our amended and restated certificate of incorporation will provide that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware), the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employee of the Company to us or our stockholders&#59; (3) any action asserting a claim against us arising pursuant to any provision of the DGCL, the Amended and Restated Certificate of Incorporation or the Bylaws of the Company&#59; or (4) any action asserting a claim against us governed by the internal affairs doctrine.  Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Company shall be deemed to have notice of and to have consented to these provisions.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Transfer Agent and Registrar</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.  The transfer agent&#8217;s address is P.O. Box 43078, Providence, Rhode Island 02940.  The transfer agent for any series of preferred stock that we may offer under this prospectus will be named and described in the prospectus supplement for that series.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Listing on The Nasdaq Capital Market</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Our common stock is listed on Nasdaq under the symbol &#8220;FLKS.&#8221;</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div></div></div><div id="i731487425af54b57bab8205021f9c376_292"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">DESCRIPTION OF DEBT SECURITIES</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt.  While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement.  The terms of any debt securities offered under a prospectus supplement may differ from the terms described below.  Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We will issue the debt securities under the indenture that we will enter into with the trustee named in the indenture.  The indenture will be qualified under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act.  We have filed the form of indenture as an exhibit to the registration statement of which this prospectus is a part.  We will file as exhibits to the registration statement of which this prospectus is a part, or will be incorporated by reference from reports that we file with the SEC, supplemental indentures and forms of debt securities containing the terms of the debt securities being offered.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The following summary of material provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities.  We urge you to read the applicable prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">General</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The indenture does not limit the amount of debt securities that we may issue.  It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate.  Except for the limitations on consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against changes in our operations, financial condition or transactions involving us.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We may issue the debt securities issued under the indenture as &#8220;discount securities,&#8221; which means they may be sold at a discount below their stated principal amount.  These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#8220;original issue discount,&#8221; or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities.  Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described in more detail in any applicable prospectus supplement.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including&#58;</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the title of the series of debt securities&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">any limit upon the aggregate principal amount that may be issued&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the maturity date or dates&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the form of the debt securities of the series&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the applicability of any guarantees&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of any subordination&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is convertible into another security or the method by which any such portion shall be determined&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">our right, if any, to defer payment of interest and the maximum length of any such deferral period&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#8217;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series&#59;</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or securities&#59; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities&#59; and the depositary for such global security or securities&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the holders&#8217; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which shall be payable upon declaration of acceleration of the maturity thereof&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">additions to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the consolidation, merger or sale covenant&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">additions to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">additions to or changes in the provisions relating to satisfaction and discharge of the indenture&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued under the indenture&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars&#59; </font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">whether interest will be payable in cash or additional debt securities at our or the holders&#8217; option and the terms and conditions upon which the election may be made&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any and principal amounts of the debt securities of the series to any holder that is not a &#8220;United States person&#8221; for federal tax purposes&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">any restrictions on transfer, sale or assignment of the debt securities of the series&#59; and</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Conversion or Exchange Rights</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We will set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities.  We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option.  We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Consolidation, Merger or Sale</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety.  However, any successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Events of Default under the Indenture</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indenture with respect to any series of debt securities that we may issue&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become due and payable, and such default continues for a period of 90 days&#59; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of interest for this purpose&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series&#59; provided, however, that a valid extension of the maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders of </font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">if specified events of bankruptcy, insolvency or reorganization occur.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately.  If an event of default specified in the last bullet point above occurs with respect to us, the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture.  Any waiver shall cure the default or event of default.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Subject to the terms of the indenture, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity.  The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the direction so given by the holder is not in conflict with any law or the applicable indenture&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">A holder of the debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the holder has given written notice to the trustee of a continuing event of default with respect to that series&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request,</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred by the trustee in compliance with the request&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We will periodically file statements with the trustee regarding our compliance with specified covenants in the indenture.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Modification of Indenture&#59; Waiver</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We and the trustee may change an indenture without the consent of any holders with respect to specific matters&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">to comply with the provisions described above under &#8220;Description of Debt Securities-Consolidation, Merger or Sale&#59;&#8221;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">to provide for uncertificated debt securities in addition to or in place of certificated debt securities&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred upon us in the indenture&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">to make any change that does not adversely affect the interests of any holder of debt securities of any series in any material respect&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided above under &#8220;Description of Debt Securities-General&#8221; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities&#59;</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee&#59; or</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected.  However, unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">extending the fixed maturity of any debt securities of any series&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption of any series of any debt securities&#59; or</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Discharge</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Each indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">provide for payment&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">register the transfer or exchange of debt securities of the series&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">replace stolen, lost or mutilated debt securities of the series&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">pay principal of and premium and interest on any debt securities of the series&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">maintain paying agencies&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">hold monies for payment in trust&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">recover excess money held by the trustee&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">compensate and indemnify the trustee&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">appoint any successor trustee.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Form, Exchange and Transfer</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We will issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof.  The indenture provides that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in the applicable prospectus supplement with respect to that series.  To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the applicable prospectus supplement.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose.  Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities.  We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">If we elect to redeem the debt securities of any series, we will not be required to&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing&#59; or</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Information Concerning the Trustee</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture.  Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs.  Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Payment and Paying Agents</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders.  Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series.  We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series.  We will maintain a paying agent in each place of payment for the debt securities of a particular series.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Governing Law</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The indenture and the debt securities will be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture Act of 1939 is applicable.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></div></div></div><div id="i731487425af54b57bab8205021f9c376_287"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">DESCRIPTION OF WARRANTS</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The following description, together with the additional information we may include in any applicable prospectus supplement and in any related free writing prospectus that we may authorize to be distributed to you, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or more series.  Warrants may be offered independently or in combination with common stock, preferred stock or debt securities offered by any prospectus supplement.  While the terms we have summarized below will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement.  The following description of warrants will apply to the warrants offered by this prospectus unless we provide otherwise in the applicable prospectus supplement.  The applicable prospectus supplement for a particular series of warrants may specify different or additional terms.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We have filed forms of the warrant agreements and forms of warrant certificates listing the terms of the warrants that may be offered as exhibits to the registration statement of which this prospectus is a part.  We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant or the warrant agreement and warrant certificate, as applicable, that contain the terms of the particular series of warrants we are offering, as well as any supplemental agreements, before the issuance of such warrants.  The following summaries of material terms and provisions of the warrants are subject to, and qualified in their entirety by reference to, all the provisions of the form of warrant or the warrant agreement and warrant certificate, as applicable, and any supplemental agreements applicable to a particular series of warrants that we may offer under this prospectus.  We urge you to read the applicable prospectus supplement related to the particular series of warrants that we may offer under this prospectus, as well as any related free writing prospectus, and the complete form of warrant or the warrant agreement and warrant certificate, as applicable, and any supplemental agreements, that list the terms of the warrants.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">General</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">In the applicable prospectus supplement, we will describe the terms of the series of warrants being offered, including, to the extent applicable&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the offering price and aggregate number of warrants offered&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the currency for which the warrants may be purchased&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable on exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased on such exercise&#59;</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable on the exercise of one warrant and the price at which these shares may be purchased on such exercise&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the terms of any rights to redeem or call the warrants&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable on exercise of the warrants&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the dates on which the right to exercise the warrants will commence and expire&#59; 22</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the manner in which the warrant agreements and warrants may be modified&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">a discussion of material or special U.S. federal income tax considerations of holding or exercising the warrants&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the terms of the securities issuable on exercise of the warrants&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable on such exercise, including&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or payments on our liquidation, dissolution or winding up or to exercise voting rights, if any&#59; or</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable on exercise or to enforce covenants in the applicable indenture.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Exercise of Warrants</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement.  The warrants may be exercised as listed in the prospectus supplement relating to the warrants offered.  Unless we otherwise specify in the applicable prospectus supplement, warrants may be exercised at any time up to the specified time on the expiration date that we list in the applicable prospectus supplement.  After the close of business on the expiration date, unexercised warrants will become void.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">On receipt of payment and the warrant or warrant certificate, as applicable, properly completed and duly executed at the corporate trust office of the warrant agent, if any, or any other office, including ours, indicated in the prospectus supplement, we will, as soon as practicable, issue and deliver the securities purchasable on such exercise.  If less than all of the warrants (or the warrants represented by such warrant certificate) are exercised, a new warrant or a new warrant certificate, as applicable, will be issued for the remaining warrants.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Governing Law</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Unless we provide otherwise in the applicable prospectus supplement, the warrants and warrant agreements will be governed by and construed in accordance with the laws of the State of New York.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Enforceability of Rights by Holders of Warrants</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Each warrant agent, if any, will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant.  A single bank or trust company may act as warrant agent for more than one issue of warrants.  A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand on us.  Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable on exercise of, its warrants.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></div></div></div><div id="i731487425af54b57bab8205021f9c376_299"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">LEGAL OWNERSHIP OF SECURITIES</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We can issue securities in registered form or in the form of one or more global securities.  We describe global securities in greater detail below.  We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee or depositary maintain for this purpose as the &#8220;holders&#8221; of those securities.  These persons are the legal holders of the securities.  We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#8220;indirect holders&#8221; of those securities.  As we discuss below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Book-Entry Holders</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement.  This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#8217;s book-entry system.  These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Only the person in whose name a security is registered is recognized as the holder of that security.  Global securities will be registered in the name of the depositary or its participants.  Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary.  The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners.  The depositary and its participants do so under agreements they have made with one another or with their customers&#59; they are not obligated to do so under the terms of the securities.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">As a result, investors in a global security will not own securities directly.  Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#8217;s book-entry system or holds an interest through a participant.  As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Street Name Holders</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We may terminate a global security or issue securities that are not issued in global form.  In these cases, investors may choose to hold their securities in their own names or in &#8220;street name.&#8221;  Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those securities to them.  These </font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so.  Investors who hold securities in street name will be indirect holders, not holders, of those securities.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Legal Holders</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Our obligations, as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal holders of the securities.  We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means.  This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">For example, once we make a payment or give a notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so.  Similarly, we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of an indenture, or for other purposes.  In such an event, we would seek approval only from the holders, and not the indirect holders, of the securities.  Whether and how the legal holders contact the indirect holders is up to the legal holders.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Special Considerations for Indirect Holders</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">If you hold securities through a bank, broker or other financial institution, either in book-entry form because the securities are represented by one or more global securities or in street name, you should check with your own institution to find out&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">how it handles securities payments and notices&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">whether it imposes fees or charges&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">how it would handle a request for the holders&#8217; consent, if ever required&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the future&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">if the securities are in book-entry form, how the depositary&#8217;s rules and procedures will affect these matters.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Global Securities</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">A global security is a security that represents one or any other number of individual securities held by a depositary.  Generally, all securities represented by the same global securities will have the same terms.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Each security issued in book-entry form will be represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we select.  The financial institution that we select for this purpose is called the depositary.  Unless we specify otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, New York, known as DTC, will be the depositary for all securities issued in book-entry form.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise.  We describe those situations below under &#8220;-Special Situations When a Global Security Will Be Terminated.&#8221;  As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security.  Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does.  Thus, an investor whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">If the prospectus supplement for a particular security indicates that the security will be issued as a global security, then the security will be represented by a global security at all times unless and until the global security is terminated.  If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Special Considerations for Global Securities</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">As an indirect holder, an investor&#8217;s rights relating to a global security will be governed by the account rules of the investor&#8217;s financial institution and of the depositary, as well as general laws relating to securities transfers.  We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">If securities are issued only as global securities, an investor should be aware of the following&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">an investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe below&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form&#59;</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">an investor may not be able to pledge his or her interest in the global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the depositary&#8217;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor&#8217;s interest in the global security&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">we and any applicable trustee have no responsibility for any aspect of the depositary&#8217;s actions or for its records of ownership interests in the global security, nor will we or any applicable trustee supervise the depositary in any way&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">financial institutions that participate in the depositary&#8217;s book-entry system, and through which an investor holds its interest in the global security, may also have their own policies affecting payments, notices and other matters relating to the securities.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">There may be more than one financial intermediary in the chain of ownership for an investor.  We do not monitor and are not responsible for the actions of any of those intermediaries.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Special Situations When a Global Security Will Be Terminated</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">In a few special situations described below, a global security will terminate and interests in it will be exchanged for physical certificates representing those interests.  After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor.  Investors must consult their own banks or brokers to find out how to have their interests in securities transferred to their own names, so that they will be direct holders.  We have described the rights of holders and street name investors above.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Unless we provide otherwise in the applicable prospectus supplement, the global security will terminate when the following special situations occur&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">if we notify any applicable trustee that we wish to terminate that global security&#59; or</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities covered by the prospectus supplement.  When a global security terminates, the depositary, and neither we nor any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></div></div></div><div id="i731487425af54b57bab8205021f9c376_305"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">PLAN OF DISTRIBUTION</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods.  We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers.  We may distribute securities from time to time in one or more transactions&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">at a fixed price or prices, which may be changed&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">at market prices prevailing at the time of sale&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">at prices related to such prevailing market prices&#59; or</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">at negotiated prices.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We may also sell equity securities covered by this registration statement in an &#8220;at the market offering&#8221; as defined in Rule 415 under the Securities Act.  Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">on or through the facilities of Nasdaq or any other securities exchange or quotation or trading service on which such securities may be listed, quoted or traded at the time of sale&#59; and&#47;or</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">other than on Nasdaq or such other securities exchanges or quotation or trading services.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Such at the market offerings, if any, may be conducted by underwriters acting as principal or agent.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities, including, to the extent applicable&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the name or names of any underwriters, dealers or agents, if any&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the purchase price of the securities and the proceeds we will receive from the sale&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">any over-allotment options under which underwriters may purchase additional securities from us&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">any agency fees or underwriting discounts and other items constituting agents&#8217; or underwriters&#8217; compensation&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">any public offering price&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">any discounts or concessions allowed or reallowed or paid to dealers&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">any securities exchange or market on which the securities may be listed.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale.  The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement.  We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate.  Subject to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement.  Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time.  We may use underwriters with whom we have a material relationship.  We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We may sell securities directly or through agents we designate from time to time.  We will name any agent involved in the offering and sale of securities, and we will describe any commissions we will pay the agent in the prospectus supplement.  Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future.  We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We may provide agents and underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities.  Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">All securities we offer, other than common stock, will be new issues of securities with no established trading market.  Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice.  We cannot guarantee the liquidity of the trading markets for any securities.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids.  Overallotment involves sales in excess of the offering size, which create a short position.  Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum.  Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions.  Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions.  Those activities may cause the price of the securities to be higher than it would otherwise be.  If commenced, the underwriters may discontinue any of the activities at any time.  These transactions may be effected on any exchange or over-the-counter market or otherwise.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Any underwriters who are qualified market makers on Nasdaq may engage in passive market making transactions in the securities on Nasdaq in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities.  Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers.  In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security&#59; if all independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market maker&#8217;s bid must then be lowered when certain purchase limits are exceeded.  Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></div></div></div><div id="i731487425af54b57bab8205021f9c376_311"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">LEGAL MATTERS</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">Unless otherwise indicated in the applicable prospectus supplement, certain legal matters in connection with the offering and the validity of the securities offered by this prospectus, and any supplement thereto, will be passed upon by Cooley LLP.  Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.</font></div><div id="i731487425af54b57bab8205021f9c376_317"></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">EXPERTS</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The consolidated financial statements of Flex Pharma, Inc. appearing in Flex Pharma, Inc.&#8217;s Annual Report (Form&#160;10-K) for the year ended December 31, 2018, have been audited by Ernst &#38; Young LLP, independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference.  Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</font></div><div id="i731487425af54b57bab8205021f9c376_323"></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">WHERE YOU CAN FIND MORE INFORMATION</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">This prospectus is part of the registration statement on Form S-3 we filed with the SEC under the Securities Act.  This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement.  For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement.  You should rely only on the information contained in this prospectus or incorporated by reference.  We have not authorized anyone else to provide you with different information.  We are not making an offer of these securities in any state where the offer is not permitted.  You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We file annual, quarterly and current reports, proxy statements and other information with the SEC.  You may read and copy the registration statement, as well as any other document filed by us with the SEC, at the SEC&#8217;s Public Reference Room at 100 F Street NE, Washington, D.C. 20549.  The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC, including Flex.  The address of the SEC website is www.sec.gov.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We maintain a website at www.flex-pharma.com.  Information contained in or accessible through our website does not constitute a part of this prospectus.</font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39</font></div></div></div><div id="i731487425af54b57bab8205021f9c376_329"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The SEC allows us to &#8220;incorporate by reference&#8221; information into this prospectus, which means that we can disclose important information to you </font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">by referring you to another document filed separately with the SEC.  The SEC file number for the documents incorporated by reference in this prospectus </font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">is 001-36812.  The documents incorporated by reference into this prospectus contain important information that you should read about us.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">The following documents are incorporated by reference into this document&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 6, 2019&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">our Annual Report on Form 10-K&#47;A for the year ended December 31, 2018, filed with the SEC on April 16, 2019&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">our Current Reports on Form 8-K filed with the SEC on January 4,  2019 and February 15, 2019, to the extent the information in such reports is filed and not furnished&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%;padding-left:32.5pt">the description of our common stock contained in our Registration Statement on Form 8-A, filed with the SEC on January 23, 2015, including any amendments or reports filed for the purposes of updating this description.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i) after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, or (ii) after the date of this prospectus but prior to the termination of the offering.  These documents include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such documents.  You may request a copy of these filings by writing us at 31 St. James Avenue, 6th Floor, Boston, MA 02116 or telephoning us at (617) 874-1821.</font></div><div><font><br></font></div><div style="height:101.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40</font></div></div></div><div id="i731487425af54b57bab8205021f9c376_22"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">9,339,436 Shares</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><img alt="image_2a.jpg" src="image_2a.jpg" style="height:104px;margin-bottom:5pt;vertical-align:text-bottom;width:282px"></div><div style="margin-bottom:48pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">Common Stock</font></div><div style="margin-bottom:48pt;text-align:center"><font><br></font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">_____________________</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">PROSPECTUS SUPPLEMENT</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">_____________________</font></div><div style="margin-bottom:12pt;margin-top:200pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:161%">Ladenburg Thalmann</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:161%">_____________________</font></div><div style="margin-bottom:48pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:161%">April 22, 2022</font></div><div style="height:102.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">    </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">   </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>2
<FILENAME>calculationoffilingfeetabl.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iad90978690d742a9ab8ab4fffb27f67d_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:128%">Exhibit 107.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:128%">Calculation of Filing Fee Tables</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:128%">424(b)(5)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:128%">(Form Type)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:128%">Salarius Pharmaceuticals, Inc. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:128%">(Exact Name of Registrant as Specified in its Charter)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:128%;text-decoration:underline">Table 1&#58; Newly Registered Securities</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Security Type</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Security Class Title</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Fee Calculation Rule</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Amount Registered</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Proposed Maximum Offering Price Per Unit</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Maximum Aggregate Offering Price</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Fee Rate</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Amount of Registration Fee</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Equity</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Common Stock</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">457(o)</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">9,339,436</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$0.25</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$2,334,859</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$92.70</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$216.44</font></td></tr><tr><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Total Offering Amounts</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Total Fee Offsets (1)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$216.44</font></td></tr><tr><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Net Fee Due</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$0.00</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:128%">(1)&#160;&#160;&#160;&#160;The shares being registered pursuant to this prospectus supplement relate to the registrant&#8217;s Registration Statement on Form S-3 (File No. 333-231010) for which a filing fee was paid for the shares registered thereunder pursuant to Rule 457(o).</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:128%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:128%"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" ". N<# 2(  A$! Q$!_\0
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MH?X\V/[/WPZU#X@:QILUU#9Q[MD! /?UKK/!UJ=,\,:;HEU%\]KIL$;#W6,
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M[&K_ -JM7];G[./_ "1+P[_V#U_F:!M'<>9[4JMN[4RG1T$CJ1FV]J6FOUH
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M)]U64G@_A7"\/.K+4^VI\19?A\+&G7>R1]AF_B1<NP7ZTX7T17<&S7YE:O\
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MP<(K=H3.[]V%JI*]N)?+VG/UJ\I4-C94<MG$S&392IJG3.CV=.5_;:GYT_\
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M?MD?_H%!?V3]B$ZTZHXV)?%24$!1110 5\N_\%8/^35?$'_7K_1J^HJ^7_\
M@JRL4W[*7B)C)C;;?T:@<=S^8G]G3_D\G2?^QJ_]JM7];G[./_)$O#O_ &#U
M_F:_DC_9V65?VP](E(&/^$LQ_P"137];7[-[AO@CX=_[!Z_S- Y'<444V1G5
M<HN302.HJ*6[CA(#=33O-+$;!\OK0!\%?\%]_P#DTN\_[:?^@"OP?_X)5?\
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M=7_!4A<>-X ?^>C?R-=E_P $NCMU&0_],7_E7'_\%2")?&\)C'_+5_Y&NO\
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M4CY:<DBB0)7QM1>\?N]./NI^1+SZ444519'12[&]*1E;' H _F%_X.9,R?\
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M-X23*GC<]QF*494Y6]#YZ^#G[/GQ$_: \0R>(?%JW'D[BV9-P'(SZUQOQM\
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M Q[48'I110  8Z"BBB@ HP#U%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
G%%% !1110 4444 %%%% !CVHHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_2a.jpg
<TEXT>
begin 644 image_2a.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" #N H8# 2(  A$! Q$!_\0
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MJ%3F/>&EV#+-4@.>E55EB#QVS#=\N<U:!&.*\N,)1W9L%%%%6 4444 %%%%
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M8=.E4_*47_T&OK_6-.M-7L)]/U.)9(7&&5NA'O7S^:2Y<R=]=2Z,?=/YLO\
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M'?X-^)H?%?CC5;B&WC96\B8R+T/3!-=%\,_^#AC]GS7VCT/QR8HI)6 V^4Y
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MWN8YM/+*5CQGG\:X\=@:D\UU6ERJ<GRGXE_M?_M5?&#]JSXV76B:5K]YY)U
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M9PM_Q]1PL%SVYS6'^Q#^UQX]^ ?Q:LI)_$-Q':-<*GER2MQC/J:_33_@J_\
M\%3?@!\1?A???#[P+JL6HWTB[5AD7"]QG(/:OR3_ &>/A9K?QA^,.EZ#8:8]
MPUSJ7S%5)"!B>:^FP_UVKE[G5CK8QA>Y_5!^SKXVC\>?!/PWXR:X$S:AID<Q
M*GUKT!/NYKRS]EOP>W@+X">#_";)MGLM$BB>/'<5ZHF=HS7Y/5J2EBIQ:M9G
MITW)QU%HHHH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBJ;520J@9XJG\;?A7I'Q2\'W7AJ[B56GB*QMTP36M\,)K2?P+I_V63C[*O\
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M=M_NV],B_:J\?I*V?"%XH_A4V_6O0)/BC\$I1YEO<P$ \\#_ !KB?C/^UO\
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M/::39[?I4_VU6[1^XG_5_#_WOO/F$_#[]KMF7?XMTS _Z=6_^*I%\!_MC+=
MCQ=I7E ]/L9S_P"A5]0;31M/K1_;-;M'[D+_ %?P_P#>^\^7F^'W[8,D>QO&
M&E[O,W#_ $1NGYT+\/OVPE,S?\)CI?S_ '?]%;C_ ,>KZ?,+ YWTH1^S5?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK!7&TTX\C%(JXYH K1Z7;02
M^>JBK0.1D5&26.#4@&!B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
<@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
